GAXOS.AI INC
GXAINASDAQTrading Snapshot
- Day Range
- $0.55 – $0.56
- 52-Week Range
- $0.51 – $2.63
- Volume
- $3.69B
- Avg Volume
- $3.56B
- Shares Outstanding
- 10.2M
- Next Earnings
- Oct 22, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $2M
- P/E Ratio
- -1.1
- P/S Ratio
- 1.0x
- EPS (TTM)
- $-0.37
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +2.5%
Why Investors Own GXAI
- ✓High-growth profile — revenue up +46.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 75% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
GAXOS.AI INC
GXAI
StockOtter · stockotter.spaceAbout GAXOS.AI INC
Gaxos.ai Inc. specializes in the creation, acquisition, and ongoing management of digital games that incorporate non-fungible tokens (NFTs). The company also oversees a dedicated digital gaming platform that features its own proprietary titles, alongside games developed and published by external partners, all presented under the Gaxos brand. In January 2024, the organization transitioned from its previous identity, The NFT Gaming Company, Inc., to its current name, Gaxos.ai Inc. Established in 2021, the firm's operations are headquartered in Roseland, New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Exagen (NASDAQ:XGN) versus Gaxos.ai (NASDAQ:GXAI) Financial Review
Exagen (NASDAQ: XGN - Get Free Report) and Gaxos.ai (NASDAQ: GXAI - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of
Gaxos.ai Inc. Raises $3.6 Million in Gross Proceeds from Warrant Exercise Transaction
Roseland, NJ, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. (NASDAQ: GXAI), (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various high-growth sectors, today announced the
Gaxos Announces Exercise of Warrants for Approximately $3.6 Million Gross Proceeds
Roseland, NJ, Aug. 14, 2026 (GLOBE NEWSWIRE) -- --Gaxos.ai Inc. (“Gaxos” or the “Company”)(NASDAQ: GXAI), a company developing artificial intelligence applications across various high-growth sectors, today announced the
Gaxos Delivers Record Second-Quarter Revenue, Up 35.8% Sequentially and 1,337% Year over Year
Revenue growth significantly outpaces advertising expense growth as revenue generated per advertising dollar improves Roseland, NJ, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company")(NASDAQ: GXAI)
Comparing Gaxos.ai (NASDAQ:GXAI) and Castle Biosciences (NASDAQ:CSTL)
Castle Biosciences (NASDAQ: CSTL - Get Free Report) and Gaxos.ai (NASDAQ: GXAI - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the
Gaxos Announces $1,000,000 Share Repurchase Plan
Roseland, NJ , Aug. 03, 2026 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company")(NASDAQ: GXAI), a company developing artificial intelligence applications across various high-growth sectors, today announced that